Mnemos EP | Jotup

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Retrieved on:

Monday, November 20, 2023

Sale, Hearing, Commercial Court, Patient, CET, Euronext Growth, Mnemos EP, Commercial Court (Victoria)

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Key Points:

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators
Paris, France, November 20, 2023 – 5:45 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, whose safeguard proceedings (procédure de sauvegarde) were converted into receivership (redressement judiciaire) by decision of the Paris Commercial Court on November 13, 2023, announces that the court-appointed administrators have today received a takeover offer for the assets and activities of Pixium.
The date for the hearing to examine the takeover offer will be set by the Commercial Court by the end of November.
The Company draws investors’ attention to the fact that, given the current offer and the Company’s level of indebtedness, the sale proceeds received in the context of the Company’s insolvency proceedings do not allow a total or partial reimbursement of shareholders.

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD

Retrieved on:

Tuesday, November 14, 2023

Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.

Key Points:

Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.
As a reminder, the Company is currently subject to receivership proceedings and is actively looking for buyers to acquire the Company’s business.
The deadline for submission of offers has been set to November 20, 2023, at 12:00 p.m. (noon) CET.
Pixium will continue to regularly inform the market on the progress of the procedure and, more generally, of Pixium Vision’s financial situation.

Pixium Vision announces the conversion of the safeguard proceedings into receivership

Retrieved on:

Monday, November 13, 2023

Interest, Commercial Court, Euronext Growth, Confidentiality, Patient, Mnemos EP, Hearing

As announced on October 18, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Pixium together with the court-appointed administrators, filed a request with the Commercial Court of Paris for the conversion of the safeguard proceedings into receivership.

Key Points:

As announced on October 18, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Pixium together with the court-appointed administrators, filed a request with the Commercial Court of Paris for the conversion of the safeguard proceedings into receivership.
This request was examined and approved by the Commercial Court of Paris at the hearing of November 13, 2023.
Interested candidates are invited to contact the court-appointed administrators, SCP Abitbol & Rousselet, represented by Joanna Rousselet, and Selarl FHB, represented Hélène Bourbouloux.
The market will be regularly informed on the progress of the procedure and, more generally, on the financial situation of Pixium.

Mnemo Therapeutics Announces Publication in Cancer Discovery on Ablation of SUV39H1 for Long-Term Protection Against Solid Tumors

Retrieved on:

Tuesday, November 7, 2023

Neoplasm, CAR, Mnemos EP, Therapy, Biotechnology, Lung cancer, SUV39H1, Immunotherapy, Gene, Memory, Longevity, Vaccine, Cancer Discovery (journal)

PARIS, Nov. 7, 2023 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, has announced a new preclinical study showing that CAR T cell memory differentiation and persistence can be enhanced by inactivating SUV39H1, an enzyme (histone methyltransferase) that epigenetically regulates and represses memory-associated genes. The paper, published in Cancer Discovery, is titled "SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors."

Key Points:

The paper, published in Cancer Discovery, is titled "SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors."
SUV39H1-inactivated CAR T cells promote long-term protection against tumor relapses and rechallenges, demonstrated in mouse models of lung cancer and other solid tumors.
"T cell exhaustion and lack of persistence impede the long-term success of immunotherapy treatments for tumors," said Mnemo Chief Executive Officer Robert LaCaze.
SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors.

Pixium Vision announces its financial results for H1 2023 and provides update

Retrieved on:

Thursday, October 26, 2023

Mnemos EP, State, Commercial Court, Bank statement, Euronext Growth, EUR, CET, Commercial Court (Victoria), European, CIC, Patient, Security (finance), Risk management, Cryptocurrency, Bpifrance

The H1 2023 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 25 October 2023.

Key Points:

The H1 2023 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 25 October 2023.
Our request for an accelerated payment of the Research Tax Credit for the year 2022 for an amount of EUR 1,829,961 was granted and paid during H1 2023.
Freeze of the maturities due under the State-guaranteed loans granted to the Company by Bpifrance and CIC was extended until end of September 2023.
Given the above, our auditors were unable to express a conclusion on the condensed half-yearly consolidated financial statements.

Pixium Vision announces the launch of a process to find buyers

Retrieved on:

Wednesday, October 18, 2023

CET, Confidentiality, Euronext Growth, Interest, Mnemos EP, Patient, Pharmaceutical industry

Having been unable to find financial investors within the restricted timeframe and in line with the Company's needs, a safeguard plan is no more an option.

Key Points:

Having been unable to find financial investors within the restricted timeframe and in line with the Company's needs, a safeguard plan is no more an option.
As a result, the Company will be requesting the conversion of safeguard proceedings (procédure de sauvegarde) into receivership (redressement judiciaire).
Interested candidates are invited to contact the court-appointed administrators, SCP Abitbol & Rousselet, represented by Joanna Rousselet, and Selarl FHB, represented by Hélène Bourbouloux.
The market will be regularly informed of developments in the procedure and, more generally, of the Company's financial situation.

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

Retrieved on:

Monday, October 23, 2023

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).

Key Points:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).
BI 770371 is an IgG1 mAb that recognizes both the V1 and V2 variants of SIRPα.
We are very pleased to potentially make our selective SIRPα inhibitor technology available to more patients through this strategic collaboration.
The first clinical results of BI 770371 presented at ESMO 2023 conference (Madrid, Abstract #697P ) showed that adverse events were manageable during the on-treatment period, Maximal Tolerated Dose (MTD) has not been reached.

Pixium Vision announces the opening of safeguard proceedings

Retrieved on:

Monday, October 9, 2023

Acquisition, Mnemos EP, Euronext Growth, Court, Risk, Bank statement, Patient, CET, Euronext Paris, Observation, Commercial Court, Research, Sale, Security (finance), Risk management

Paris, France, October 9, 2023 – 19:00 (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX) (the “Company”), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the opening today of safeguard proceedings by the Commercial Court of Paris.

Key Points:

Paris, France, October 9, 2023 – 19:00 (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX) (the “Company”), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the opening today of safeguard proceedings by the Commercial Court of Paris.
Considering such liquidity risk over a maximum 2-month horizon and the absence of new financing to date, Pixium Vision therefore requested the opening of safeguard proceedings with the Commercial Court of Paris.
In this context, Pixium Vision has applied to Euronext Paris for the resumption of the listing of its shares as of the opening of the markets on October 10, 2023.
As a consequence of the opening of such safeguard proceedings, the Company is not in a position to publish its H1 2023 condensed financial statements, which will therefore be published at a later date.

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

Retrieved on:

Monday, October 16, 2023

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Key Points:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
Silvia Comis, Head of Clinical Development and Regulatory Affairs of OSE Immunotherapeutics, comments: “These first efficacy and safety positive results from clinical Phase 1/2 assessing the therapeutic potential of our proprietary anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors are very promising.
These results encourage further clinical development of OSE-279 in the future as a monotherapy treatment in pre-identified cancer niche indications, with still high unmet medical needs.
This product will also be available for combination with other OSE drug candidates or with external assets opening new potential partnerships.”
The communication reported on the first positive results from the Phase 1/2 clinical trial evaluating OSE-279 monotherapy in patients with advanced solid tumors, with no therapeutic option available.

Pixium Vision announces the completion of the reverse stock split of its shares on the basis of 1 new share for 50 existing shares and the start of trading of the shares resulting after the completion of the reverse split as of Sep 21, 2023

Retrieved on:

Wednesday, September 20, 2023

Exercise, Note, Micromax IN Note 1, US, Parity, Acquisition, Patient, Bulletin, Warrant, ISIN, Mnemos EP, Cryptocurrency, Security (finance)

All operations relating to the reverse stock split will be carried out on Euronext Growth Paris via Société Générale Securities Services, 32 rue du Champ de Tir, CS 30812, 44308 Nantes Cedex 3, appointed as agent to centralize the reverse stock split operations.

Key Points:

All operations relating to the reverse stock split will be carried out on Euronext Growth Paris via Société Générale Securities Services, 32 rue du Champ de Tir, CS 30812, 44308 Nantes Cedex 3, appointed as agent to centralize the reverse stock split operations.
The terms and timetable of the reverse stock split were set out in a press release published on July 28, 2023.
A notice was published in the French legal notice gazette (Bulletin des annonces légales obligatoires or BALO) on August 4, 2023 (no.
The Company continues to actively seek financing options to support its strategic ambitions.